nih:ovcar-3 Search Results


ovcar3 cells  (ATCC)
99
ATCC ovcar3 cells
A) Quantification of Cetuximab, an IgG1 Ab, binding to <t>OVCAR3</t> cells as compared to patient TBAs by fluorescence. Cetuximab was incorporated at concentrations of 0.01–0.1 µg/mL. B) Quantification of Cetuximab binding to FcγRIIIa as compared to patient TBAs via fluorescence. C) Percent cytotoxicity of unmodified patient TBAs, quantified by an in vitro effector response assay (n=36). All patient TBAs were normalized to the same concentration. Cetuximab was used as a positive control (+). NK cells co-incubated with OVCAR3 cells alone functioned as the negative control (-). A purple bar indicates a patient that was evaluated in A) and B). Data are represented as average ± standard deviation. See also Figure S4.
Ovcar3 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nih%3Aovcar-3/NIH%3AOVCAR-3/bio_rxiv__64898__2026__04__25__720834-184-0-2
Average 99 stars, based on 1 article reviews
ovcar3 cells - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
ovcar  (AMS Biotechnology)
96
AMS Biotechnology ovcar
A) Quantification of Cetuximab, an IgG1 Ab, binding to <t>OVCAR3</t> cells as compared to patient TBAs by fluorescence. Cetuximab was incorporated at concentrations of 0.01–0.1 µg/mL. B) Quantification of Cetuximab binding to FcγRIIIa as compared to patient TBAs via fluorescence. C) Percent cytotoxicity of unmodified patient TBAs, quantified by an in vitro effector response assay (n=36). All patient TBAs were normalized to the same concentration. Cetuximab was used as a positive control (+). NK cells co-incubated with OVCAR3 cells alone functioned as the negative control (-). A purple bar indicates a patient that was evaluated in A) and B). Data are represented as average ± standard deviation. See also Figure S4.
Ovcar, supplied by AMS Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nih%3Aovcar-3/NIH%3AOVCAR-3+%5BOVCAR3%5D+Cell+Line/10__1016_slash_j__tet__2020__131754-274-5-29
Average 96 stars, based on 1 article reviews
ovcar - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
human ovarian adenocarcinoma cell line  (ATCC)
96
ATCC human ovarian adenocarcinoma cell line
A) Quantification of Cetuximab, an IgG1 Ab, binding to <t>OVCAR3</t> cells as compared to patient TBAs by fluorescence. Cetuximab was incorporated at concentrations of 0.01–0.1 µg/mL. B) Quantification of Cetuximab binding to FcγRIIIa as compared to patient TBAs via fluorescence. C) Percent cytotoxicity of unmodified patient TBAs, quantified by an in vitro effector response assay (n=36). All patient TBAs were normalized to the same concentration. Cetuximab was used as a positive control (+). NK cells co-incubated with OVCAR3 cells alone functioned as the negative control (-). A purple bar indicates a patient that was evaluated in A) and B). Data are represented as average ± standard deviation. See also Figure S4.
Human Ovarian Adenocarcinoma Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nih%3Aovcar-3/NIH%3AOVCAR-3%3B+Ovarian+Adenocarcinoma%3B+Human/bio_rxiv__2024__06__24__600360-95-0-6
Average 96 stars, based on 1 article reviews
human ovarian adenocarcinoma cell line - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
nih:ovcar-3 cell  (BioResource International Inc)
90
BioResource International Inc nih:ovcar-3 cell
A) Quantification of Cetuximab, an IgG1 Ab, binding to <t>OVCAR3</t> cells as compared to patient TBAs by fluorescence. Cetuximab was incorporated at concentrations of 0.01–0.1 µg/mL. B) Quantification of Cetuximab binding to FcγRIIIa as compared to patient TBAs via fluorescence. C) Percent cytotoxicity of unmodified patient TBAs, quantified by an in vitro effector response assay (n=36). All patient TBAs were normalized to the same concentration. Cetuximab was used as a positive control (+). NK cells co-incubated with OVCAR3 cells alone functioned as the negative control (-). A purple bar indicates a patient that was evaluated in A) and B). Data are represented as average ± standard deviation. See also Figure S4.
Nih:Ovcar 3 Cell, supplied by BioResource International Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nih%3Aovcar-3/nih+ovcar+3+cell/pmc04552561-42-0-7
Average 90 stars, based on 1 article reviews
nih:ovcar-3 cell - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
nih:ovcar-3 cell avalanche transfection reagent  (EZ Biosystems)
90
EZ Biosystems nih:ovcar-3 cell avalanche transfection reagent
A) Quantification of Cetuximab, an IgG1 Ab, binding to <t>OVCAR3</t> cells as compared to patient TBAs by fluorescence. Cetuximab was incorporated at concentrations of 0.01–0.1 µg/mL. B) Quantification of Cetuximab binding to FcγRIIIa as compared to patient TBAs via fluorescence. C) Percent cytotoxicity of unmodified patient TBAs, quantified by an in vitro effector response assay (n=36). All patient TBAs were normalized to the same concentration. Cetuximab was used as a positive control (+). NK cells co-incubated with OVCAR3 cells alone functioned as the negative control (-). A purple bar indicates a patient that was evaluated in A) and B). Data are represented as average ± standard deviation. See also Figure S4.
Nih:Ovcar 3 Cell Avalanche Transfection Reagent, supplied by EZ Biosystems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nih%3Aovcar-3/nih+ovcar+3+cell+avalanche+transfection+reagent/pmc05823659-127-10-18
Average 90 stars, based on 1 article reviews
nih:ovcar-3 cell avalanche transfection reagent - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
1/cddp nih:ovcar-3 adenocarcinoma, ascites metastasis  (PharmaCell)
90
PharmaCell 1/cddp nih:ovcar-3 adenocarcinoma, ascites metastasis
A) Quantification of Cetuximab, an IgG1 Ab, binding to <t>OVCAR3</t> cells as compared to patient TBAs by fluorescence. Cetuximab was incorporated at concentrations of 0.01–0.1 µg/mL. B) Quantification of Cetuximab binding to FcγRIIIa as compared to patient TBAs via fluorescence. C) Percent cytotoxicity of unmodified patient TBAs, quantified by an in vitro effector response assay (n=36). All patient TBAs were normalized to the same concentration. Cetuximab was used as a positive control (+). NK cells co-incubated with OVCAR3 cells alone functioned as the negative control (-). A purple bar indicates a patient that was evaluated in A) and B). Data are represented as average ± standard deviation. See also Figure S4.
1/Cddp Nih:Ovcar 3 Adenocarcinoma, Ascites Metastasis, supplied by PharmaCell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nih%3Aovcar-3/nih+ovcar+3+adenocarcinoma++ascites+metastasis/us11083774-15-207-209
Average 90 stars, based on 1 article reviews
1/cddp nih:ovcar-3 adenocarcinoma, ascites metastasis - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
ovarian adenocarcinoma cell line nih:ovcar-3 (htb161)  (LGC Promochem)
90
LGC Promochem ovarian adenocarcinoma cell line nih:ovcar-3 (htb161)
A) Quantification of Cetuximab, an IgG1 Ab, binding to <t>OVCAR3</t> cells as compared to patient TBAs by fluorescence. Cetuximab was incorporated at concentrations of 0.01–0.1 µg/mL. B) Quantification of Cetuximab binding to FcγRIIIa as compared to patient TBAs via fluorescence. C) Percent cytotoxicity of unmodified patient TBAs, quantified by an in vitro effector response assay (n=36). All patient TBAs were normalized to the same concentration. Cetuximab was used as a positive control (+). NK cells co-incubated with OVCAR3 cells alone functioned as the negative control (-). A purple bar indicates a patient that was evaluated in A) and B). Data are represented as average ± standard deviation. See also Figure S4.
Ovarian Adenocarcinoma Cell Line Nih:Ovcar 3 (Htb161), supplied by LGC Promochem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nih%3Aovcar-3/ovarian+adenocarcinoma+cell+line+nih+ovcar+3++htb161+/pm18719363-125-1-10
Average 90 stars, based on 1 article reviews
ovarian adenocarcinoma cell line nih:ovcar-3 (htb161) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
nih:ovcar-3 cells  (Biochrom)
90
Biochrom nih:ovcar-3 cells
A) Quantification of Cetuximab, an IgG1 Ab, binding to <t>OVCAR3</t> cells as compared to patient TBAs by fluorescence. Cetuximab was incorporated at concentrations of 0.01–0.1 µg/mL. B) Quantification of Cetuximab binding to FcγRIIIa as compared to patient TBAs via fluorescence. C) Percent cytotoxicity of unmodified patient TBAs, quantified by an in vitro effector response assay (n=36). All patient TBAs were normalized to the same concentration. Cetuximab was used as a positive control (+). NK cells co-incubated with OVCAR3 cells alone functioned as the negative control (-). A purple bar indicates a patient that was evaluated in A) and B). Data are represented as average ± standard deviation. See also Figure S4.
Nih:Ovcar 3 Cells, supplied by Biochrom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nih%3Aovcar-3/nih+ovcar+3+cells/pmc04425222-47-2-8
Average 90 stars, based on 1 article reviews
nih:ovcar-3 cells - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
nih-ovcar3  (Broad Institute Inc)
90
Broad Institute Inc nih-ovcar3
A) Quantification of Cetuximab, an IgG1 Ab, binding to <t>OVCAR3</t> cells as compared to patient TBAs by fluorescence. Cetuximab was incorporated at concentrations of 0.01–0.1 µg/mL. B) Quantification of Cetuximab binding to FcγRIIIa as compared to patient TBAs via fluorescence. C) Percent cytotoxicity of unmodified patient TBAs, quantified by an in vitro effector response assay (n=36). All patient TBAs were normalized to the same concentration. Cetuximab was used as a positive control (+). NK cells co-incubated with OVCAR3 cells alone functioned as the negative control (-). A purple bar indicates a patient that was evaluated in A) and B). Data are represented as average ± standard deviation. See also Figure S4.
Nih Ovcar3, supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nih%3Aovcar-3/nih+ovcar3/pm36899893-385-2-40
Average 90 stars, based on 1 article reviews
nih-ovcar3 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
nih: ovcar-3  (AcceGen Biotechnology)
N/A
Tumorigenecity: Isoenzyme: G6PD, B; PGM1, 1; PGM3, 1; ES D, 1; AK1, 1; GLO-1, 1Histopathology: adenocarcinomaSubculture: Split ratio: Media change: Reverse transcritase: Production.
   Buy from Supplier
nih ovcar 3 ovcar3 cell line  (Elabscience)
N/A
   Buy from Supplier

Image Search Results


A) Quantification of Cetuximab, an IgG1 Ab, binding to OVCAR3 cells as compared to patient TBAs by fluorescence. Cetuximab was incorporated at concentrations of 0.01–0.1 µg/mL. B) Quantification of Cetuximab binding to FcγRIIIa as compared to patient TBAs via fluorescence. C) Percent cytotoxicity of unmodified patient TBAs, quantified by an in vitro effector response assay (n=36). All patient TBAs were normalized to the same concentration. Cetuximab was used as a positive control (+). NK cells co-incubated with OVCAR3 cells alone functioned as the negative control (-). A purple bar indicates a patient that was evaluated in A) and B). Data are represented as average ± standard deviation. See also Figure S4.

Journal: bioRxiv

Article Title: Systems serology of responses against tumor antigens in ovarian cancer reveal disrupted Fc-mediated immunity

doi: 10.64898/2026.04.25.720834

Figure Lengend Snippet: A) Quantification of Cetuximab, an IgG1 Ab, binding to OVCAR3 cells as compared to patient TBAs by fluorescence. Cetuximab was incorporated at concentrations of 0.01–0.1 µg/mL. B) Quantification of Cetuximab binding to FcγRIIIa as compared to patient TBAs via fluorescence. C) Percent cytotoxicity of unmodified patient TBAs, quantified by an in vitro effector response assay (n=36). All patient TBAs were normalized to the same concentration. Cetuximab was used as a positive control (+). NK cells co-incubated with OVCAR3 cells alone functioned as the negative control (-). A purple bar indicates a patient that was evaluated in A) and B). Data are represented as average ± standard deviation. See also Figure S4.

Article Snippet: OVCAR3 cells (ATCC HTB-161) were grown in complete growth media.

Techniques: Binding Assay, Fluorescence, In Vitro, Concentration Assay, Positive Control, Incubation, Negative Control, Standard Deviation